Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov site footer revision changes from v3.8.0 to v3.8.1, with no change to the study details.SummaryDifference0.0%

- Check11 days agoChange DetectedThe record for this completed ovarian cancer study is now displayed, including its treatment regimens, eligibility criteria, locations, outcomes, and study documents.SummaryDifference73%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 error.SummaryDifference0.2%

- Check32 days agoChange DetectedA site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check39 days agoChange DetectedThe footer now displays site revision v3.7.2 instead of v3.7.1. The study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check46 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.